PMID: 9449276Feb 4, 1998Paper

Treatment of histoplasmosis with MK-991 (L-743,872)

Antimicrobial Agents and Chemotherapy
J R GraybillM J Rinaldi

Abstract

BALB/c nu/+ immunocompetent and athymic (nu/nu) mice were infected intravenously with yeast cells of Histoplasma capsulatum. Mice were either given water (controls) intraperitoneally (i.p.) or given MK-991 i.p. once daily or twice daily. Protection was measured as prolonged survival or reduction in tissue counts. MK-991 was protective in immunocompetent mice, prolonging survival and reducing counts in spleen and livers at a dose as low as 0.05 mg/kg of body weight/day. MK-991 was modestly effective in athymic mice at a higher dose, 5 mg/kg/day. These studies suggest that MK-991 may be appropriate for clinical development in histoplasmosis.

References

Nov 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E AnaissieG Bodey
Mar 1, 1990·Reviews of Infectious Diseases·H A GallisW W Pickard
Dec 1, 1987·Antimicrobial Agents and Chemotherapy·G S KobayashiG Medoff
Aug 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J Wheat
Jan 27, 1994·The New England Journal of Medicine·J A Como, W E Dismukes
Apr 15, 1993·Annals of Internal Medicine·J WheatUNKNOWN National Institute of Allergy and Infectious Diseases Clinical Trials and Mycoses Study Group Collaborators

❮ Previous
Next ❯

Citations

Jan 5, 2002·Expert Opinion on Investigational Drugs·A H Groll, T J Walsh
Feb 7, 2002·Expert Opinion on Pharmacotherapy·Francisco Marty, Eleftherios Mylonakis
Aug 2, 2002·Expert Opinion on Pharmacotherapy·Carol A Kauffman
May 27, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stanley C Deresinski, David A Stevens
Oct 7, 2005·Expert Review of Anti-infective Therapy·Vicki A Morrison
Nov 8, 2018·Evidence-based Complementary and Alternative Medicine : ECAM·Jiehua DengXiaolu Wang
May 18, 2020·Chinese Journal of Integrative Medicine·Jie-Hua DengGang-Sheng Wang
Feb 15, 2001·Expert Opinion on Investigational Drugs·N H Georgopapadakou
Apr 20, 2002·Current Opinion in Infectious Diseases·E G Arathoon
Nov 30, 2000·Current Infectious Disease Reports·A V Jacobs, H L Leaf
Feb 4, 2003·Expert Opinion on Pharmacotherapy·Jason C GallagherJohn R Perfect
May 13, 2003·Expert Opinion on Pharmacotherapy·Melissa D Johnson, John R Perfect
Jul 29, 2003·Expert Opinion on Investigational Drugs·Nathan P Wiederhold, Russell E Lewis
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Marta Feldmesser
Nov 4, 2000·Expert Opinion on Investigational Drugs·M A Hossain, M A Ghannoum
Dec 8, 2005·Proceedings·Joseph Rybowicz, Cheryle Gurk-Turner
Apr 7, 2006·Expert Review of Anti-infective Therapy·Vicki A Morrison
Sep 7, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L Joseph WheatUNKNOWN Infectious Diseases Society of America
Feb 19, 2002·Antimicrobial Agents and Chemotherapy·K V ClemonsD A Stevens
Oct 6, 1999·Current Opinion in Microbiology·B DiDomenico

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Antimicrobial Agents and Chemotherapy
J R GraybillM Luther
Antimicrobial Agents and Chemotherapy
J R GraybillF G de las Heras
Antimicrobial Agents and Chemotherapy
J R GraybillD Loebenberg
The American Review of Respiratory Disease
R L TaylorW E Magee
© 2021 Meta ULC. All rights reserved